33
Participants
Start Date
May 29, 2025
Primary Completion Date
January 31, 2028
Study Completion Date
January 31, 2028
Encorafenib + Binimetinib
Induction treatment with oral encorafenib 450 mg once daily (QD) + binimetinib 45 mg twice daily (BID)(combination: EB) for approximately two months (i.e. 8 weeks)
cemiplimab+fianlimab
cemiplimab 350 mg + fianlimab 1600 mg combination every 3 weeks (Q3W)(Combination: CF) administered to patients intravenously (IV) for up to two years.
RECRUITING
Hospital Universitario San Pedro de Alcántara, Cáceres
RECRUITING
Complejo Hospitalario Universitario A Coruña, A Coruña
RECRUITING
Onkologikoa (Donostia), Donostia / San Sebastian
NOT_YET_RECRUITING
Hospital Universitario Gregorio Marañon, Madrid
RECRUITING
Hospital Universitario Ramón y Cajal, Madrid
RECRUITING
Hospital Clinico San Carlos, Madrid
RECRUITING
Hospital Universitario Puerta del Hierro, Majadahonda
RECRUITING
Hospital Regional Universitario de Málaga, Málaga
RECRUITING
Clinico Universitario Virgen de la Arrixaca, Murcia
RECRUITING
Hospital Universitario Marqués de Valdecilla, Santander
RECRUITING
Hospital Virgen de la Macarena (Sevilla), Seville
RECRUITING
Hospital Clínico Universitario Valencia., Valencia
RECRUITING
Hospital General Universitario de Valencia, Valencia
RECRUITING
Quiron Dexeus - IOR, Barcelona
RECRUITING
Hospital Universitario Vall d´Hebron, Barcelona
RECRUITING
Hospital Clínic de Barcelona, Barcelona
RECRUITING
Instituto Catalán de Oncología - Hospital Duran i Reynals, Barcelona
RECRUITING
Hospital Universitario de Burgos, Burgos
Collaborators (1)
Regeneron Pharmaceuticals
INDUSTRY
MFAR
OTHER
Pierre Fabre Laboratories
INDUSTRY
Grupo Español Multidisciplinar de Melanoma
OTHER